北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 药剂科  > 期刊论文
学科主题: 临床医学
题名:
Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects
作者: Cui, Yi-min1; Wang, Zi-ning1; Chen, Xiao-wen2; Zhang, Hui-lin1; Zhao, Xia1; Zhou, Ying1
关键词: prasugrel ; platelet aggregation ; pharmacokinetics ; pharmacodynamics ; dose regimen ; healthy Chinese subject
刊名: ACTA PHARMACOLOGICA SINICA
发表日期: 2012-11-01
DOI: 10.1038/aps.2012.120
卷: 33, 期:11, 页:1395-1400
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Chemistry, Multidisciplinary ; Pharmacology & Pharmacy
研究领域[WOS]: Chemistry ; Pharmacology & Pharmacy
关键词[WOS]: P2Y(12) RECEPTOR ANTAGONIST ; ACUTE CORONARY SYNDROMES ; ANTIPLATELET AGENT ; CLOPIDOGREL ; PHARMACOLOGY
英文摘要:

Aim: To characterize the pharmacokinetics (PKs), pharmacodynamics (PDs), and tolerability of different dose regimens of prasugrel in healthy Chinese subjects.

Methods: This was a single-centered, open-label, parallel-design study. Subjects received a single loading dose (LD) of prasugrel followed by once-daily maintenance dose (MD) for 10 d. They were enrolled into 3 groups: 60 mg LD/10 mg MD; 30 mg LD/7.5 mg MD; 30 mg LD/5 mg MD. Blood samples were collected after the first and last dose. The serum concentration of the active metabolite of prasugrel was determined using a LC/MS/MS method. Platelet aggregation was assessed using the VerifyNow-P2Y(12) assay.

Results: Thirty-six healthy native Chinese subjects (19 males) aged 18-45 were enrolled; mean age and body weight were similar across the treatment groups (n=12 for each). The metabolite AUC(0-4) and C-max increased dose-proportionally across the dose range of 5 mg to 60 mg. The median T-max was 0.5 h in all groups. The PD parameters, indicated by the inhibition of ADP-induced platelet aggregation, were met more rapidly in the 60 mg group than the 30 mg group after the LD (94%-98%). This high degree of inhibition of platelet aggregation was maintained following the 10 mg MD (87%-90%) and was lower in the 7.5 mg and 5 mg MD groups (79%-83% and 64%-67%, respectively). Prasugrel was well tolerated in healthy Chinese subjects for single doses up to 60 mg and a MD of 10 mg for 10 d.

Conclusion: The PKs and PDs of the active metabolite of prasugrel were similar to those in Chinese subjects reported by a previous bridging study, which demonstrated that the exposure to the active metabolite in Chinese subjects was higher than in Caucasians.

语种: 英语
项目资助者: Eli Lilly and Company, Indianapolis, Indiana, USA
WOS记录号: WOS:000310778400009
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/61596
Appears in Collections:北京大学第一临床医学院_药剂科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Hosp 1, Dept Pharm, Base Clin Trial, Beijing 100034, Peoples R China
2.Lilly Suzhou Pharmaceut Co Ltd, Shanghai 200021, Peoples R China

Recommended Citation:
Cui, Yi-min,Wang, Zi-ning,Chen, Xiao-wen,et al. Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects[J]. ACTA PHARMACOLOGICA SINICA,2012,33(11):1395-1400.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Cui, Yi-min]'s Articles
[Wang, Zi-ning]'s Articles
[Chen, Xiao-wen]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Cui, Yi-min]‘s Articles
[Wang, Zi-ning]‘s Articles
[Chen, Xiao-wen]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace